We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

BECKMAN COULTER, INC.

Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App





Beckman Coulter Highlights Latest Innovations in Clinical Diagnostics at WHX Labs Dubai

By LabMedica International staff writers
Posted on 11 Feb 2026

Beckman Coulter Diagnostics (Brea, CA, USA) is showcasing its broad portfolio of laboratory analyzers and workflow solutions at WHX Labs Dubai 2026, demonstrating how continued innovation is helping laboratories deliver fast, consistent, and reliable diagnostic results. More...

At booth S2.G10, the company is spotlighting its featured product, the DxC 500i Clinical Analyzer, an integrated clinical chemistry and immunoassay system designed to maximize performance. The space-saving platform supports independently operating chemistry and immunoassay testing, reagent load-on-the-fly functionality, rapid throughput, and FlexMode Maintenance, enabling laboratories to maintain productivity even during peak workloads.

The DxC 500i delivers time to first results in as few as eight minutes for chemistry tests and 18 minutes for immunoassay panels such as β-hCG. Random access functionality helps accelerate priority samples, while a broad and expanding assay menu across chemistry and immunoassay provides a comprehensive view of disease states from a single analyzer. Standardized, right-sized reagent packs further support consistent, high-quality results while minimizing waste, backed by Six Sigma performance assays.

Also featured is the award-winning DxI 9000 Access Immunoassay Analyzer, which introduces first-of-its-kind high-sensitivity immunoassay testing for core laboratories. With throughput of up to 450 tests per hour, optimized reagent utilization, and enhanced traceability, the system is designed to accelerate time to answers while amplifying overall laboratory productivity. Real-time insights and high system availability help laboratories meet rising testing demands with confidence.

In addition to its diagnostic capabilities, the DxI 9000 is engineered to streamline laboratory operations. Its ZeroDaily Maintenance design eliminates the need for routine daily maintenance, reducing annual maintenance activities by up to 96% and allowing staff to focus more time on testing and patient care.

Related Links:
Beckman Coulter


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic Hematology Analyzer
DH-800 Series
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.